Table 3.
Association between pericardial disease and mortality in those treated with and without ICI
| Deaths (n) | Time to death days (IQR) |
HR | P value | ||
| Patients treated with ICI (n=2842) | No pericardial disease (n=2800) | 1143 | 134 (54–276) | Reference | |
| Pericardial disease (n=42) | 26 | 148 (56–356) | 1.53 (1.04 to 2.26) | 0.03 | |
| Patients not treated with an ICI (n=2699) | No pericardial disease (n=2678) | 1401 | 843 (278– 1839) | Reference | |
| Pericardial disease (n=21) | 14 | 857 (642–2981) | 1.21 (0.71 to 2.05) | 0.48 | |
| Patients treated with ICI who were alive at 6 weeks (n=2621) | No pericardial disease (n=2584) | 927 | 187 (92–325) | Reference | |
| Pericardial disease (n=37) | 21 | 186 (83–256) | 1.53 (0.99 to 2.36) | 0.05 | |
| Patients not on an ICI who were alive at 6 weeks (n=2640) | No pericardial disease (n=2619) | 1342 | 893 (330–1882) | Reference | |
| Pericardial disease (n=21) | 14 | 857 (643–2981) | 1.26 (0.74 to 2.13) | 0.39 | |
ICI, immune checkpoint inhibitor.